Advaxis Secures $23 Million Financing

Last week, Advaxis, Inc. (a clinical-stage biotechnology company developing cancer immunotherapies on its proprietary Lm-LLO platform technology), announced that a combined $23 million of purchase agreements was raised, worth approximately 3.1 million shares, at a price of $7.50 per share from several institutional investors. The investors include Adage Capital Management, L.P. Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and …

NW Bio Announces German Early Access and Reimbursement Approvals for DCVax-L

DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator March 10, 2014  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has received approval from the Paul Ehrlich Institute (“PEI”- the FDA of Germany) of a “Hospital Exemption” early access program under Section 4b of the …

Infographic: Therapeutic Cancer Vaccines – Ones to watch

As Cancer Vaccines Month draws to a close here on Vaccine Nation, we’ve taken a look at the promising cancer vaccines currently in late stage clinical trials. The current crop of cancer vaccines builds upon the lessons learnt from earlier disappointments, and employs new and novel approaches whilst amending endpoints and clinical objectives to better represent the realistic and measurable …

Interview: Analysing the potential for DNA vaccines

Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals was kind enough to take the time to speak to us to give his viewpoint on DNA Vaccines, in particular, their potential across a range of cancer indication. What is the potential for DNA vaccines across a broad range of cancer indications? It’s a great time to be in the DNA vaccine arena. There’s a …

Agenus’ brain cancer vaccine impresses in Phase II

US biotech Agenus has announced encouraging results from a Phase II trial of its brain cancer vaccine. Things had taken a turn for the worse for Lexington-based Agenus at the start of the month, as it was announced that a late-stage trial with GSK's MAGE-A3 melanoma cancer vaccine – for which it made the adjuvant – had failed to meet …

Good news for Dendreon, Provenge gets EU approval

After a troubled time across the pond, Dendreon has been granted European marketing authorisation for its prostate cancer vaccine Provenge. The immunotherapy, also known as sipuleucel-T, got the final approval from the European Commission yesterday, following recent thumbs-ups from the EMA's Committee for Advanced Therapy (CAT) and the Committee for Medicinal Products for Human  Use (CHMP). The marketing authorisation was …

250 vaccines in development, including these Phase III cancer vaccines

According to the "Biologics 2013 Report" by Pharmaceutical Research and Manufacturers of America (PhRMA), there are 250 vaccines in development, including 134 vaccines for infectious diseases. The list of vaccines in development includes several cancer vaccines in Phase III development, including: Personalized dendritic cell vaccine for metastatic renal cancer (AGS-003; Argos Therapeutics) Dendritic cell vaccine for glioblastoma(DCVax-L; Northwest Biotherapeutics) Vaccine …

Commercial, clinical and regulatory challenges in development of cancer vaccines – opportunities and solutions

The need for a Cancer vaccine is undisputed. As a leading cause of mortality worldwide, it is important that we work towards an effective cure and/or treatment. Some forms of cancer masquerade as a chronic disease and current passive immunotherapy only partially addresses clinical needs. Difficulties in producing an effective vaccine have arisen as Cancer vaccines are more complex medicines …